Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HAGH | Q16775 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4054011 | 0.91 | LMNA (0.51) | DAOLMNATSHRCYP2C19CYP1A2 | |
| SCHEMBL4049551 | 0.83 | TSHR (0.63) | DAOLMNATSHRCYP2C19ALDH1A1 | |
| SCHEMBL10368266 | 0.75 | CYP2C19 (0.45) | DAOLMNACYP2C19CYP1A2CYP3A4 | |
| SCHEMBL29125948 | 0.74 | KMT2A (0.53) | LMNATSHRCYP2C19CYP1A2CYP3A4 | |
| SCHEMBL5797843 | 0.72 | TSHR (0.54) | DAOLMNATSHRCYP2C19ALDH1A1 | |
| SCHEMBL12474423 | 0.72 | DAO (0.73) | DAOLMNATSHRCYP2C9ALDH1A1 | |
| SCHEMBL6306047 | 0.71 | CYP2C19 (0.59) | LMNACYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7909121 | 0.71 | CYP2C19 (0.59) | LMNACYP2C19CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29125771 | 0.70 | KMT2A (0.54) | LMNATSHRCYP2C19CYP1A2CYP3A4 | |
| SCHEMBL28965534 | 0.69 | CYP2C19 (0.57) | LMNACYP2C19CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090299066-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | ERIKSSON ANDERS | 2009-12-03 | — | — | US | disclosed |
| EP-1732903-B1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-20070219217-A1 | Triazolone Derivatives as Mmp Inhibitors for the Treatment of Asthma and Copd | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | US | disclosed |
| EP-1732903-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | AstraZeneca AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005095362-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | ASTRAZENECA AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219217-A1 | Triazolone Derivatives as Mmp Inhibitors for the Treatment of Asthma and Copd | MMP9, MMP3, MMP25 | DAO 1266/4885LMNA 528/4885TSHR 1214/4885 |
| US-20090299066-A1 | TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD | MMP3, MMP9, MMP25 | DAO 1022/4885LMNA 568/4885TSHR 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.